Dr. Kamel is the Helen and Albert Moon Professor of Neurology and Neuroscience at Weill Cornell Medicine and directs the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute. Dr. Kamel attended college at Harvard and medical school at Columbia, then trained as a neurology resident and neurocritical care fellow at UCSF before joining Weill Cornell Medicine in 2011. He has published >450 scientific papers, including in leading journals such as NEJM, JAMA, and Cell, resulting in >30,000 citations and an h-index of 82. His research program is primarily focused on uncovering the relationship between atrial cardiopathy and stroke. He was the protocol principal investigator for the NIH-funded ARCADIA trial, which was the first randomized trial to test the hypothesis of a thrombogenic atrial cardiopathy. He is a principal investigator of the NIH-funded ASPIRE trial, which is testing antithrombotic strategies in patients with atrial fibrillation and intracerebral hemorrhage. As an internationally recognized leader in the intersection of cardiology and neurology, he serves on the steering committees of several major global cardiovascular trials such as LIBREXIA-AF, REACT-AF, INTERCEPT, and LAAOS-4. He has been invited to give >70 national and international lectures about his scientific work on the relationship between cardiac disease and stroke. He serves on the NIH StrokeNet Executive Committee and chairs its Prevention Working Group. He directs the Weill Cornell Laboratory for Understanding Cerebral Injury via Imaging and Data Science (LUCID), which is conducting several NIH-funded studies to develop cutting-edge imaging techniques for neurological disorders. He is the Deputy Editor of JAMA Neurology and his academic contributions have been recognized by the Robert G. Siekert Award, the Joseph A. Vita Award, and the Stroke Council Award from the American Heart Association and the Michael S. Pessin Prize from the American Academy of Neurology.